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Primary hyperoxaluria type 1 (PH1) is an atypical peroxisomal disorder, as befits a deficiency of alanine:glyoxylate aminotransferase (AGT),
which is itself an atypical peroxisomal enzyme. PH1 is characterized by excessive synthesis and excretion of the metabolic end-product oxalate
and the progressive accumulation of insoluble calcium oxalate in the kidney and urinary tract. Disease in many patients is caused by a unique
protein trafficking defect in which AGT is mistargeted from peroxisomes to mitochondria, where it is metabolically ineffectual, despite remaining
catalytically active. Although the peroxisomal import of human AGT is dependent upon the PTS1 import receptor PEX5p, its PTS1 is exquisitely
specific for mammalian AGT, suggesting the presence of additional peroxisomal targeting information elsewhere in the AGT molecule. This and
many other functional peculiarities of AGT are probably a consequence of its rather chequered evolutionary history, during which much of its time
has been spent being a mitochondrial, rather than a peroxisomal, enzyme. Analysis of the molecular basis of AGT mistargeting in PH1 has thrown
into sharp relief some of the fundamental differences between the requirements of the peroxisomal and mitochondrial protein import pathways,
particularly the properties of peroxisomal and mitochondrial matrix targeting sequences and the different conformational limitations placed upon
importable cargos.
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hyperoxaluria type 11. PH1 and AGT deficiency
Primary hyperoxaluria type 1 (PH1, MIM 259900) is a rare
autosomal recessive disorder of metabolism caused by a
functional deficiency of the liver-specific, pyridoxal-phos-
phate-dependent enzyme alanine:glyoxylate aminotransferase
(AGT, EC 2.6.1.44) [1]. In the peroxisomes of normal human
hepatocytes, AGT catalyses the transamination of the interme-
diary metabolite, glyoxylate, to glycine. This can be considered
to be a detoxification reaction because its dysfunction in PH1
allows glyoxylate to escape from the peroxisomes into the
cytosol where it is oxidised to oxalate, catalysed by lactate
dehydrogenase, and reduced to glycolate, catalysed by glyox-
ylate/hydroxypyruvate reductase (Fig. 1) [2,3]. In humans, at
least, oxalate cannot be further metabolised and its increased
synthesis and urinary excretion leads to the progressiveE-mail address: c.danpure@ucl.ac.uk.
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.08.021deposition of insoluble calcium oxalate (CaOx) in the kidney
and urinary tract, as various combinations of nephrocalcinosis
(diffuse deposition throughout the renal parenchyma) and/or
urolithiasis (calculi or stones). This eventually leads to renal
failure, following which the combined effects of increased
oxalate synthesis and failure to remove it from the body results in
the deposition of CaOx almost anywhere. The clinical
presentation of PH1 is heterogeneous, for example with respect
to age of first symptom, levels of urinary oxalate and glycolate
excretion, relative contributions of nephrocalcinosis and uro-
lithiasis, and rate of progression of renal pathology.
2. Relationship between genotype and enzyme phenotype
2.1. The structure of normal AGT
Human AGT is a homodimeric protein, each subunit being
composed of 392 amino acids with a molecular mass of about
Fig. 1. Metabolic consequences of peroxisomal AGT deficiency in PH1. AGT, alanine:glyoxylate aminotransferase; DAO, D-amino acid oxidase; GO, glycolate oxidase;
GRHPR, glyoxylate/hydroxypyruvate reductase; LDH, lactate dehydrogenase. Solid arrows, metabolic conversions; dotted arrows, membrane or other transport.
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1H0C) (Fig. 2) shows that each subunit can be subdivided into
three recognizable structural/functional domains. The first 20 or
so residues make up an N-terminal extension that wraps over the
surface of the other subunit. The next 260 or so residues form
the ‘large domain’ that contains most of the active site and the
dimerization interface. The final C-terminal ‘small domain’
consists of about 110 residues, which contains among other
things the principal and ancillary peroxisomal targeting
information [6,7] (see below). Each subunit binds one pyridoxal
phosphate, which forms a Schiff base with Lys209. The large
surface area of the dimerization interface explains the high
stability of the AGT dimer. Although the inter-subunit
interaction mediated by the N-terminal extension is unlikely
to make any major contribution to stability to the dimer onceFig. 2. Crystal structure of human AGT. The two identical subunits are mainly colou
NH2, amino termini; KKL, carboxy-terminal PTS1s. The location of the cofactor pyrid
polymorphism (11 in pink), and the mutations discussed in the text (41, 82, 170, 244
the Pro11Leu polymorphism.formed, it is believed to play a significant role in the
dimerization process per se [5]. Dimerization of AGT is very
important, not only because monomeric AGT has vastly
reduced catalytic activity [8], but also because it is unstable
leading to aggregation and rapid degradation [9]. Knowledge of
the crystal structure of AGT has provided insights into the
processes of AGT folding, dimerization and catalytic activity, as
well as allowing rationalisation of the effects mutations and
polymorphisms on these processes (see below).
2.2. Enzyme phenotypes in PH1
The clinical heterogeneity of PH1 is matched, or possibly
even exceeded, by its enzymatic heterogeneity. Three overt
categories can be identified:-deficiency of AGTcatalytic activityred yellow, except for the N-terminal extensions (red) and the PTS1As (green).
oxal phosphate is indicated (PLP in orange), as are the locations of the Pro11Leu
in blue). It is the N-terminal extension (red) that acts as a MTS in the presence of
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activity and immunoreactivity, and deficiency of neither
catalytic activity nor immunoreactivity. Patients in the latter
category can have AGT levels up to half the mean normal level,
which is well within the normal range and greater than found in
many asymptomatic carriers [2]. Intermediate categories also
exist, in which patients have markedly reduced, but still
detectable levels of catalytic activity and/or immunoreactivity.
More detailed analysis shows the presence of two enzyme
phenotypes unique to PH1. In a small group of patients with
almost no AGT catalytic activity and markedly reduced AGT
immunoreactivity, AGT appears to have aggregated into intra-
peroxisomal ‘cores’ [9]. In another, much larger, group of
patients who have significant levels of AGTcatalytic activity and
immunoreactivity, an even more remarkable enzyme phenotype
is found in which AGT is mistargeted from its normal location
in the peroxisomes to the mitochondria [10]. Although
mistargeted AGT remains catalytically active, it appears to be
metabolically inefficient. This is because efficient glyoxylate
detoxification must occur at its site of synthesis (i.e. in the
peroxisomes), thus preventing its oxidation to oxalate, catalysed
by cytosolic LDH. Such organelle-to-organelle mistargeting, in
which both the normal and abnormal compartments require the
protein to contain specific, yet different, targeting information,
is without parallel in human genetic disease.
2.3. The normal AGXT gene
In humans, AGT is encoded by the AGXT gene, which
consists of 11 exons spanning about 10 kB on chromosome
2q37.3 [11]. There are two main allelic variants, the frequencies
of which vary between different populations. The less common
“minor” AGXT allele differs from the more common “major”
allele by the presence of a 32C→T (Pro11Leu) replacement in
exon 1, a 1020A→G (Ile340Met) replacement in exon 10, and
a 74 bp duplication in intron 1 [12,13]. In uncharacterized
European and North American populations, the minor allele has
a frequency of about 15–20%. However, it rises to 28% in the
Saami in Northern Sweden and falls to only 2–3% in some far
eastern populations in India, China and Japan [14,15]. Although
the Ile340Met replacement and the intron 1 duplication have no
obvious effects on the expression or properties of AGT, the
Pro11Leu polymorphism certainly does [8,12]. Firstly, it leads
to a decrease in AGT stability, which is manifested by slower
dimerization, especially at elevated temperatures [8,16].
Secondly, it decreases specific catalytic activity of recombinant
purified AGT by a factor of two to three [8]. Thirdly, it redirects
a small proportion (∼5%) of AGT away from peroxisomes
towards the mitochondrial matrix [12]. Fourthly, it sensitises
AGT to the untoward effects of many of the mutations found in
PH1 that are predicted to be innocuous in its absence [8] (see
below).
2.4. Mutations in the AGXT gene
Well over fifty mutations have been identified so far in the
AGXT gene, about half of which are point missense mutations[17]. Some of the most common co-segregate and functionally
interact with the common Pro11Leu polymorphism of the minor
allele. Many of the better-studied mutations, or mutation–
polymorphism combinations, are associated with specific
enzyme phenotypes, such as loss of AGT catalytic activity,
AGT aggregation, accelerated AGT degradation, and peroxi-
some-to-mitochondrion AGT mistargeting. The most exten-
sively studied genotype–enzyme phenotype relationships are
described in more detail below.
2.4.1. Gly82Glu
The Gly82Glu mutation is associated with complete loss of
AGT catalytic activity, without any effect on enzyme stability,
dimerization or targeting [18,19]. Structural analysis shows this
to be due to the mutant glutamate side chain filling the space
that should be occupied by the cofactor pyridoxal phosphate [5].
This prevents Shiff base formation with the ε-amino group of
Lys209, thereby abolishing catalytic activity [8]. Despite lack of
enzyme activity, patients homozygous for Gly82Glu have
completely normal levels of normally compartmentalised
immunoreactive AGT protein. Unlike many of the missense
mutations in PH1, the Gly82Glu replacement is always found
on the background of the major AGXT allele.
2.4.2. Gly41Arg
The Gly41Arg mutation has been found on the background
of both the major and minor AGXT alleles [9,20]. However,
there is some evidence to suggest that when present on the
minor allele (i.e. in the presence of the Pro11Leu polymor-
phism) the effects of this mutation are more severe [8]. At least
on the minor allele, Gly41Arg destabilizes AGT so that it is
rapidly degraded. The protein that manages to escape
degradation aggregates into intra-peroxisomal core-like struc-
tures [9]. Structural analysis shows that Gly41 sits right in the
middle of the dimerization interface, making contact with its
opposite number in the other subunit (see Fig. 2) [5]. There is
not enough room at this location to accommodate the large
arginine side-chain without causing major disruption to the
interface, thereby inhibiting dimerization. The monomer has
greatly reduced specific catalytic activity [8] and is predicted to
be unstable, one consequence of which would be aggregation
due to artefactual polymerization. The presence of aggregates
only within the peroxisomal matrix suggests that either
aggregation is slow and does not occur until after peroxisomal
import or, perhaps more probably, aggregates forming in the
cytosol, but not the peroxisomes, are rapidly degraded.
2.4.3. Ile244Thr
The second most common missense mutation is an Ile244Thr
replacement which segregates with the minor allele (i.e. with the
Pro11Leu polymorphism). This mutation has an overall allelic
frequency of about 6–9% in PH1 patients [21], but in some
parts of Spain, such as La Gomera in the Canary Islands, it is
very much higher [22]. The combined presence of the
polymorphism and the mutation appears to destabilize AGT
leading to its rapid degradation. Homozygous patients have
little or no enzyme activity or immunoreactive protein.
Table 1
C-terminal tripeptides of some PTS1 mammalian enzymes
Species Enzyme
AGT CAT UO ACO GO DAO
Human and other primates KKL ANL SRL SKL SKI SHL
Rat and other murine rodents NKL* ANL SRL SKL SKI SHL
Guinea Pig HRL* ANL SKL SHL
Rabbit SQL* SHL
Cat NKL*
Dog HKL* ANL SKL* SKL SKI PHL*
Cow SKL* ANL SRL SKL SKI
Pig SRL SHL
Koala SKL
Number of different PTS1s 6 1 2 1 1 2
AGT, alanine:glyoxylate aminotransferase; CAT, catalase; UO, urate oxidase;
ACO, acyl CoA oxidase; GO, glycolate oxidase; DAO, D-amino acid oxidase.
C-terminal tripeptides different from that in the human sequence are indicated
with asterisks. The subcellular distribution of all the peroxisomal enzymes,
except AGT, is presumed to be invariantly peroxisomal (possibly with a
proportion in the cytosol). AGT, on the other hand, is peroxisomal in human and
some other primates, including the Great Apes, Old World Monkeys, and one
New World monkey (saki monkey), guinea pig, rabbit and koala, mainly
mitochondrial in cat and dog, and both peroxisomal and mitochondrial in
marmoset (a New World monkey), rat and other murine rodents.
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containing Pro11Leu and Ile244Thr has been found to
aggregate in transfected COS cells [22], as it does when over-
expressed in E. coli [8].
2.4.4. Gly170Arg
By far the most common mutation found so far in PH1 is a
Gly170Arg replacement [12], with an estimated allelic
frequency between 15 and 35%, depending on the particular
population [12,17]. This mutation segregates exclusively with
the minor AGXT allele, and is predicted to have no untoward
effects in the absence of the Pro11Leu polymorphism [8].
Gly170Arg and Pro11Leu, together, are responsible for the
mistargeting of 90–95% of the AGT from its normal location in
the peroxisomes to the mitochondrial matrix [10]. The
mechanism by which this remarkable trafficking defect is
achieved highlights some of the most fundamental differences
between the peroxisomal and mitochondrial protein import
pathways (see Section 3 below).
3. Molecular and cell biological basis for AGT targeting
and mistargeting
3.1. Normal peroxisomal targeting of human AGT
AGT in humans and guinea pigs has been shown to be post-
translationally imported into the peroxisomal matrix in a Pex5p-
dependent and Pex7p-independent manner [6,23]. Like many
other peroxisomal enzymes [24–26], AGT folds and dimerizes
in the cytosol, and is imported into peroxisomes already in a
fully active state [27]. Despite these similarities, it is clear that
AGT is not a typical PTS1 protein. The C-terminal tripeptide in
human AGT is KKL. Although this varies from the prototypical
PTS1 SKL only at the − 3 position, all the evidence suggests
that this tripeptide should not be able to act as a PTS1. For
example, although KKL is necessary for the peroxisomal
targeting of human AGT [6], it is insufficient to direct the
peroxisomal import of reporter proteins, such as firefly
luciferase, jellyfish green fluorescent protein (GFP), and
bacterial chloramphenicol acetyltransferase [6,7,28]. KKL is
even unable to direct the peroxisomal import of non-
mammalian AGT, such as that from the amphibian Xenopus
laevis [29]. This difficulty is compounded by the observations
obtained from the crystal structure of the TPR domain of human
Pex5p that lysine at −3 could not possibly fit [30].
These findings, together with the observations that the
peroxisomal import of human AGT can actually be inhibited
by over-expression of Pex5p [31] and that the C-terminal
tripeptides of mammalian AGTs are very poorly conserved
compared to other PTS1 proteins (see Table 1), suggested that
human AGT might contain additional peroxisomal targeting
information that allows such an unconventional PTS1 to work.
A putative region of human AGT that might contain this
ancillary peroxisomal targeting information (termed PTS1A)
has been identified in the small domain, 47–68 residues
upstream of the C-terminus [7] (Fig. 2). Although further
upstream than any other sequence currently known toinfluence the efficiency of a PTS1, reference to the crystal
structure of human AGT [5] (Fig. 2) shows that the PTS1A is
actually in close proximity to the C-terminal KKL. How the
PTS1A might work is unclear, but it might involve increasing
the stability of the KKL-TPR interaction, or possibly directly
or indirectly allosterically modifying the TPR domain so that
KKL fits.
3.2. Abnormal mitochondrial targeting of human AGT
The peroxisome-to-mitochondrion mistargeting of AGT in
PH1 requires the combined presence in cis of the common
Pro11Leu polymorphism and the disease-specific Gly170Arg
mutation [12]. Surprisingly, however, the polymorphism
appears to have a much greater effect on the properties of
AGT than does the mutation (see above). The Pro11Leu
replacement generates a functionally-weak N-terminal mito-
chondrial matrix targeting sequence (MTS), the effective
strength of which is enhanced by the additional presence of
the Gly170Arg replacement [16,32].
MTSs are very different from PTS1s. They are much larger
(typically 20–30 residues), N-terminal, and, although in
different mitochondrial proteins they show little or no sequence
conservation, they all have a tendency to fold into positively-
charged amphiphilic α-helices [33]. MTSs bind to a hydropho-
bic pocket in the outer-membrane mitochondrial import
receptor TOM20 [34,35]. Also unlike PTS1s, MTSs are almost
invariably cleaved after import [36]. The N-terminal sequence
of human AGT (MASHKLLVTPPKALLKPLSI) has some
similarities to a MTS, for example, absence of acidic residues,
and a good distribution of basic, neutral or hydrophobic, and
hydroxyl amino acids. However, the presence of two neigh-
bouring helix breakers (i.e. prolines) at residues 10 and 11 is
likely to prevent this sequence from folding into an α-helix. A
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terminus of human AGT to better adopt the conformation
required for a MTS, even though circular dichroism showed that
the tendency of the purified 20-mer polypeptide to form a α-
helix was hardly any different with or without the replacement.
When both prolines were replaced by leucines, the purified 20-
mer showed a strong tendency to form an α-helix [16].
The interesting thing about this polymorphic MTS (i.e. with
the single Pro11Leu replacement) is that it is only functionally
weak when attached to AGT, whereas it is functionally strong
when attached to GFP. However, when both prolines are
replaced by leucine, it is strong irrespective of what it is
attached to [16]. The reason for this appears to be due to the fact
that AGT folds quickly and rapidly forms a stable dimer that
does not readily exchange subunits [27]. This fully-folded
dimeric conformation, although compatible with peroxisomal
protein import (see above), is incompatible with mitochondrial
protein import [37,38]. Therefore, despite the presence of an N-
terminal MTS, most of the polymorphic AGT is actually
targeted to peroxisomes due to the presence of the C-terminal
PTS1 (and PTS1A). In other words, polymorphic AGT still
folds and dimerizes faster than mitochondrial import. This
kinetic partitioning of polymorphic AGT and its perturbation
due to the additional presence of the Gly170Arg mutation is
crucial to the understanding of the peroxisome-to-mitochondri-
on mistargeting of AGT in PH1 (Fig. 3).
On its own, the disease-specific Gly170Arg mutation
provides no additional mitochondrial targeting information,
does not directly interfere with peroxisomal targeting, and has
no major effect on AGT stability or dimerization [8,27].
However, the combined effect of the Gly170Arg and Pro11Leu
replacements is to severely delay productive folding andFig. 3. Kinetic partitioning of AGT. Most of the newly-synthesized normal AGTenco
activity rapidly in the cytosol before import into peroxisomes. About 5% of normal p
AGTare imported into mitochondria before having a chance to fold and dimerize. Aft
is presumed that homologous sets of molecular chaperones mediate folding in the c
folding and dimerization in the cytosol (*) leads to its redirection along the other pathw
is present.dimerization long enough to allow the import of AGT into the
mitochondria mediated by the polymorphic MTS.
Surprisingly, unlike almost all other proteins targeted to the
mitochondrial matrix, including AGT in many other species
(see below), the polymorphic MTS of mistargeted human AGT
is not cleaved after import. The polymorphic MTS is located in
the N-terminal segment which wraps over the surface of the
companion subunit and is thought to be important in the process
of dimerization (see above and Fig. 2). The fact that it is not
cleaved means that mistargeted AGT is still able to eventually
fold and dimerize within the mitochondrial matrix, where it is
able to acquire relatively normal catalytic activity, if not
metabolic efficiency.
This explanation for the peroxisome-to-mitochondrion
mistargeting of AGT in PH1 highlights two of the fundamental
differences in the peroxisomal and mitochondrial protein import
pathways, namely the differences between the natures and
locations of the respective targeting sequences, and the different
conformational requirements of importable cargos. Interesting-
ly, mistargeted AGT contains both a N-terminal MTS and a C-
terminal PTS1 (+PTS1A). Yet, 90–95% of the enzyme ends up
in the mitochondria rather than the peroxisomes. The reason for
this is unclear, but might be due to there being more
mitochondria (and mitochondrial import receptors) than
peroxisomes (and peroxisomal import receptors), or the
mitochondrial import process might be intrinsically faster than
that of the peroxisomes, or the N-terminal location of the MTS
might make it potentially available for operation before the C-
terminal PTS1 has been synthesized. This apparent hierarchical
dominance of the MTS over the PTS1 is also found with more
conventional MTSs, such as those in other mammalian AGTs
(see below).ded by the major and minor AGXTalleles folds, dimerizes and acquires catalytic
olymorphic (Pro11Leu) AGT and about 90% of mutant (Pro11Leu+Gly170Arg)
er import into mitochondria, relatively normal folding and dimerization occurs. It
ytosol and mitochondrial matrix, but not the peroxisomes. Retardation of AGT
ays, including import into mitochondria (+) if the polymorphic (Pro11Leu) MTS
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Pro11Leu replacement does not interfere enough with AGT
folding and dimerization to generate a functionally strong MTS.
If it did, then PH1 would have a frequency of 1 in 25 (the
frequency of Pro11Leu homozygosity) rather than somewhere
between 1 in 105 and 106. The same would apply if it were not
the case that mitochondria are only able to import unfolded or
loosely-folded monomeric polypeptides [37], unlike peroxi-
somes that seem to be able to import almost anything as long as
it contains a PTS [39].
3.3. Evolutionary history of AGT targeting
The finding that AGT is mistargeted from peroxisomes to
mitochondria in a large subset of PH1 patients was surprising
not least because there are many mammals which have most of
their AGT in mitochondria anyway without apparently
succumbing to CaOx kidney stone disease [40,41].
For the vast majority of non-cytosolic eukaryotic proteins,
compartmentalisation is presumed to have occurred early in
eukaryotic evolution, the consequence of this being that the
same protein has the same subcellular distribution in all
organisms. AGT, on the other hand, can be found in
peroxisomes, mitochondria, peroxisomes and mitochondria,
peroxisomes and cytosol, and mitochondria and cytosol
[29,40,42]. During the evolution of mammals, and possibly
vertebrates in general, AGT targeting has been under the
influence of strong, yet episodic, dietary selection pressure.
Thus AGT tends to be mitochondrial in carnivores, peroxisomal
in herbivores, and both peroxisomal and mitochondrial in
omnivores. The peroxisomal location of AGT in humans is
probably a hangover from our mainly herbivorous Great Ape
ancestry [43].Fig. 4. Diet and the intracellular compartmentalization of AGT in mammals. The m
glyoxylate in the peroxisomes, catalysed by glycolate oxidase (GO). In carnivores,
number of steps, the last of which catalysed by 4-hydroxy-2-ketoglutarate aldolase (HK
at its site of synthesis. Therefore, alanine:glyoxylate aminotransferase (AGT) is best lo
lactate dehydrogenase.There is a good metabolic reason why the subcellular
distribution of AGT might be related to diet. In order to detoxify
glyoxylate efficiently, AGT must be located at the site of
glyoxylate synthesis. This site is predicted to be related to diet.
In herbivores, the main dietary precursor of glyoxylate is
thought to be glycolate [44], whereas in carnivores it is thought
to be hydroxyproline [45]. Glycolate is converted to glyoxylate
in the peroxisomes, catalysed by glycolate oxidase. On the other
hand, the last step in the conversion of hydroxyproline to
glyoxylate, catalysed by 4-hydroxy-2-ketoglutarate aldolase
[46], occurs in the mitochondria. Thus, the best place for AGT
to be is in the peroxisomes in herbivores and mitochondria in
carnivores (Fig. 4).
In all of the mammals studied so far, AGT is encoded by a
single copy gene that can encode a polypeptide varying from 392
to 414 amino acids [4,11,23,29,47–50]. The archetypal
mammalian AGT gene, as found in the rat or marmoset, for
example, has the potential to encode an N-terminal mitochon-
drial matrix targeting sequence (MTS) of 22 amino acids, and an
atypical C-terminal type 1 peroxisomal targeting sequence
(PTS) of three amino acids. There appears to be a hierarchical
dominance of the MTS over the PTS, so that if present together
the former predominates [51]. The eventual localisation of AGT
appears to be dependent on whether or not the MTS is contained
within the open reading frame, and therefore present in the
encoded polypeptide. Expression of the MTS appears to be
dependent on the relative use of two transcription start sites and
two in-frame translation start sites [52] (Fig. 5). In many species,
including the rat and marmoset, both transcription and
translation start sites have been maintained, so that two
transcripts and two polypeptides are produced. The longer,
containing the MTS and PTS is targeted mainly to the
mitochondria, whereas the shorter containing only the PTS isajor precursor of glyoxylate in herbivores is glycolate which is converted to
the major precursor is hydroxyproline, which is converted to glyoxylate by a
A) occurs in the mitochondria. Efficient detoxification of glyoxylate must occur
cated in the peroxisomes in herbivores and the mitochondria in carnivores. LDH,
Fig. 5. Archetypal mammalian AGT gene. The figure shows a diagrammatic representation of the gene encoding AGT (AGXT) in mammals. The bars indicate the
coding regions. The regions encoding the N-terminal mitochondrial matrix targeting sequence (MTS) is shown in blue, the C-terminal PTS1 in red, and the internal
PTS1A in red cross-hatched. The numbers 1 and 2 indicate the two in-frame translation start sites 22 codons apart. The letters A and B indicate the locations of the two
groups of transcription start sites. In most mammals, the MTS is 19–24 amino acids, the PTS1 3 amino acids, and in humans the PTS1A is ∼22 amino acids long.
Transcription start site A is lost in guinea pig and site B is lost in cat. Translation start site 1 is lost in human, rabbit, guinea pig and saki monkey, but site 2 is never lost.
A, B, 1, and 2 are all maintained in marmoset and rat.
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as human, rabbit, guinea pig, and saki monkey, the MTS is
permanently excluded from the open reading frame by the
evolutionary loss of the more 5′ translation start site
[4,23,43,48]. In these animals, AGT is exclusively peroxisomal.
In other species, such as the domestic cat, almost all nascent
polypeptides contain a MTS due to the loss of the more 3′
transcription start site [47]. AGT in the cat is 90–95%
mitochondrial. In certain species, such as the giant panda,
although AGT contains a MTS, it does not work very efficiently
due to the accumulation of interfering mutations that decrease its
net positive charge and weaken its potential to fold into an α-
helix [41].
The unique evolutionary history of AGT targeting might be,
at least in part, responsible for the unusual properties of this
PTS1 enzyme, especially the poor conservation of its C-
terminus and, in some species at least, its lack of sufficiency
[6,7]. Although the presence of the PTS1A might remove some
of the selection pressure to conserve the PTS1 (see above), it is
equally possible that during the evolution of vertebrates, or
mammals in particular, periods of carnivory and strong
mitochondrial targeting have diminished the need for efficient
peroxisomal targeting, so that the PTS1 might have had to have
evolved on more than one occasion.
4. AGTand idiopathic calcium oxalate kidney stone disease
As described above, the Pro11Leu polymorphism has
significant effects on the properties of AGT, most of which
might be considered detrimental. Yet, in apparently normal
European and North American populations its allelic frequency
is 20% or more. In such populations, 4% of individuals would
be expected to be homozygous for Pro11Leu. This high
frequency of what might appear to be a detrimental polymor-
phism suggests that under certain circumstances it might
actually be beneficial. The evolutionary studies outlinedabove would suggest one possible benefit, but only for those
individuals who eat a lot of meat, might be the presence of a
small amount of AGT in the mitochondria. If true then dietary
lifestyle might have contributed to the differential evolution of
this polymorphism in different human populations. In this
context, it is interesting to note that the population with the
highest frequency of Pro11Leu so far studied (i.e. 27% in the
Saami) is also the population with by far the greatest proportion
of meat in the diet. At the other extreme, populations in India,
China and Japan have frequencies of only 2–3% [15].
Monogenic CaOx kidney stone diseases, such as PH1 are
very rare, but multifactorial idiopathic CaOx kidney stone
disease is very common [54,55]. We have speculated in the past
that the presence or absence of Pro11Leu polymorphism might
be a contributory factor in an individual's susceptibility to
idiopathic CaOx kidney stones. The consequences of its
dysfunction in PH1 clearly demonstrate that AGT is an
important determinant of the rate of oxalate synthesis and
excretion, and elevated oxalate excretion is a well-known risk
factor for CaOx stones [56]. Thus the polymorphism might be
beneficial to high meat-eaters, but neutral, or possibly
detrimental, to vegetarians.
5. Postscript
AGT, or at least human AGT, fits well into a scholarly
volume on peroxisomes. However, in a wider evolutionary
context it could just as easily fit into a volume on mitochondria.
The variable peroxisomal and mitochondrial targeting of AGT
during mammalian evolution, and the peroxisome-to-mitochon-
drion mistargeting of AGT in human hereditary kidney stone
disease, place AGT in a unique position in the comparative
study of peroxisomal and mitochondrial protein import.
Whether AGT is truly unique, or whether there are any other,
as yet unidentified, enzymes that behave in a similar fashion
remains to be seen.
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